These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 7162457)

  • 1. Brook Lodge Symposium on "The pharmacology of Cytosar-U as it relates to its therapeutic usage". Kalamazoo, Michigan, December 13-15, 1981.
    Med Pediatr Oncol; 1982; 10 Suppl 1():1-272. PubMed ID: 7162457
    [No Abstract]   [Full Text] [Related]  

  • 2. CYTOSAR-U sterile powder: therapeutic biological effects. Proceedings of a symposium. November 30-December 2, 1986, Kalamazoo, MI.
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):1-275. PubMed ID: 3589683
    [No Abstract]   [Full Text] [Related]  

  • 3. Current and future aspects on the clinical use of Ara-C in leukemia. Proceedings from a symposium held at the 3rd European Conference on Clinical Oncology and Cancer Nursing, June 19, 1985, in Stockholm.
    Scand J Haematol Suppl; 1986; 44():1-74. PubMed ID: 3457436
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytarabine.
    Betcher DL; Burnham N
    J Pediatr Oncol Nurs; 1990 Oct; 7(4):154-7. PubMed ID: 2081008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular pharmacodynamics of anticancer drugs.
    Plunkett W; Gandhi V
    Semin Oncol; 1993 Feb; 20(1):50-63. PubMed ID: 8475410
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cytarabine: mechanism of action and clinical application].
    Eridani S
    Haematologica; 1972; 57(7):341-58. PubMed ID: 4628582
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of acute leukemia with newly synthesized N4-behenoyl-l-beta-D-arabinofuranosylcytosine (BH-AC) (author's transl)].
    Sueyama H; Oguro M; Takagi T
    Rinsho Ketsueki; 1981 Jul; 22(7):1109-15. PubMed ID: 7328768
    [No Abstract]   [Full Text] [Related]  

  • 8. Male fertility during chemotherapy for acute leukemia.
    Matthews JH; Wood JK
    N Engl J Med; 1980 Nov; 303(21):1235. PubMed ID: 7421954
    [No Abstract]   [Full Text] [Related]  

  • 9. [Update on malignant hematologic diseases].
    Marie JP; Delmer A
    Bull Cancer; 1998 Jan; 85(1):42-4. PubMed ID: 9752345
    [No Abstract]   [Full Text] [Related]  

  • 10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance management of acute nonlymphocytic leukemia.
    Lewis JP; Pajak TF; Linman JW; Bateman JR
    Cancer Clin Trials; 1981; 4(2):115-24. PubMed ID: 7249249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brook Lodge symposium on prostaglandins. Moderator's summary.
    Samuelsson B
    J Reprod Med; 1972 Dec; 9(6):376-7. PubMed ID: 4648915
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention of neuroleukemia by intrathecal administration of cytosar and methotrexate in acute lymphoblastic leukemia in adults].
    Filatov LB; Konstantinova TS; Shalaev VA
    Ter Arkh; 1999; 71(10):38-40. PubMed ID: 10612172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypoplastic leukemia successfully treated by oral administration with cytarabine ocfosfate].
    Okuyama Y; Kitazume K; Iwabe K; Usuki K; Urabe A
    Rinsho Ketsueki; 1994 Jun; 35(6):593-7. PubMed ID: 8078195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Itraconazole in leukemic patients with invasive aspergillosis (IA): impact on intensive chemotherapy completion.
    Nosari A; Cantoni S; Muti G; Cairoli R; Cipriani D; de Cataldo F
    Eur J Haematol; 1994 Sep; 53(3):183-5. PubMed ID: 7925864
    [No Abstract]   [Full Text] [Related]  

  • 17. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
    Estlin EJ; Yule SM; Lowis SP
    Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.
    Bornhäuser M; Illmer T; Le Coutre P; Pursche J; von Bonin M; Freiberg-Richter J; Schaich M; Platzbecker U; Thiede C; Ottmann OG; Köhne Ch; Braess J; Ehninger G; Schleyer E
    Ann Hematol; 2004; 83 Suppl 1():S61-4. PubMed ID: 15124675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia.
    Braess J; Fiegl M; Lorenz I; Waxenberger K; Hiddemann W
    Clin Cancer Res; 2005 Oct; 11(20):7415-25. PubMed ID: 16243815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the LRP (lung resistance-related protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine.
    Komarov PG; Shtil AA; Holian O; Tee L; Buckingham L; Mechetner EB; Roninson IB; Coon JS
    Oncol Res; 1998; 10(4):185-92. PubMed ID: 9778689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.